Content area
Full Text
AnaptysBio has committed to moving peanut allergy drug ANB020 into a phase 2b trial after getting a look at data from a small proof-of-concept study. But the size of the trial and AnaptysBio’s analysis of the data leave scope for questions about the strength of the findings and their implications for the anti-IL-33 antibody.
Investigators enrolled 20 patients they classed as having moderate-to-severe peanut allergies and randomized them to receive a single dose of ANB020 or placebo on a three-to-one basis. Seven of the 15 patients in the treatment arm tolerated a 500mg cumulative...